Published: 04-12-2017

We searched the heoro.com database to identify studies reporting the  indirect costs associated with psoriasis and psoriatic arthritis,  and the geographical settings in which these studies were conducted. We ran the search from 1960 to 1st June 2017 and analysed the abstracts identified by the search to determine the range of geographical locations, disease types,  interventions and study methodologies. We presented the findings as an evidence map.

Download a free copy of the Evidence Map here. To use the Map, open it in Microsoft Excel and enable macros.

We found a total of 57 abstracts. Of these, 14 reported indirect costs, including productivity losses, from the USA, 6 from Germany, 5 each from Italy and the UK, 3 each from Canada and the Netherlands, and 8 were reviews of the international literature.

Studies reporting indirect costs in psoriasis and psoriatic arthritis: geographical location by disease

Forty-one abstracts assessed indirect costs associated with plaque psoriasis and 19 psoriatic arthritis. Twenty nine abstracts reported on observational cost of illness studies or those with patient-reported productivity assessments, 9 included indirect costs in an economic model, 7 assessed indirect costs as part of a clinical  trial and 12 were reviews of the literature.

Studies reporting indirect costs in psoriasis and psoriatic arthritis: intervention by disease

Interventions studied included targeted therapies, in particular adalimumab (8 abstracts), etanercept (8), ustekinumab (5)and infliximab (3), phototherapy (6 abstracts), corticosteroids (4) and cyclosporine (2), although no specific treatment was cited in 28 abstracts.

Studies reporting indirect costs in psoriasis and psoriatic arthritis: geographical location by intervention

Two papers were published before 2000, 16 between 2000 and 2009, and 39 between 2010 and 2017.

Studies reporting indirect costs in psoriasis and psoriatic arthritis: year of publication by disease

As with many diseases, there is a relative lack of published data on indirect costs of psoriasis and psoriatic arthritis, and 53% of studies reporting indirect cost data were from four jurisdictions: the US, Germany, the UK and Italy.

Download a free copy of the Evidence Map here. To use the Map, open it in Microsoft Excel and enable macros.

We offer our Evidence Map generation service as part of our literature review consultancy work. To find out more, please contact heoro@crystallise.com.